What is the treatment for Clostridium difficile (C. difficile) colonitis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 2, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Clostridium difficile Colitis

For non-severe C. difficile infection, use oral vancomycin 125 mg four times daily for 10 days or fidaxomicin 200 mg twice daily for 10 days as first-line therapy; metronidazole is no longer recommended as first-line treatment. 1, 2

Disease Severity Classification

Before selecting treatment, classify disease severity using objective laboratory criteria:

  • Non-severe CDI: White blood cell count ≤15,000 cells/mL AND serum creatinine <1.5 mg/dL 1, 2
  • Severe CDI: White blood cell count ≥15,000 cells/mL OR serum creatinine ≥1.5 mg/dL 1, 2
  • Fulminant CDI: Hypotension, shock, ileus, or megacolon 2

The European Society of Clinical Microbiology and Infectious Diseases also includes marked leukocytosis, elevated creatinine (>50% above baseline), or decreased albumin (<30 g/L) as markers of severe disease. 1

Treatment Algorithm by Severity

Non-Severe Disease (Initial Episode)

First-line options (both have strong recommendation with high-quality evidence):

  • Oral vancomycin 125 mg four times daily for 10 days 3, 1
  • Fidaxomicin 200 mg twice daily for 10 days 3, 1, 4

Fidaxomicin offers lower recurrence rates compared to vancomycin (except for PCR ribotype 027 strains), making it preferable when available despite higher cost. 3, 2

Metronidazole 500 mg three times daily for 10 days should only be used when access to vancomycin or fidaxomicin is limited, and only for non-severe disease. 3, 1 This represents a significant change from older guidelines—metronidazole is no longer first-line therapy.

Severe Disease (Initial Episode)

Oral vancomycin 125 mg four times daily for 10 days is the treatment of choice. 1, 2

In severe disease, vancomycin demonstrated a 97% cure rate versus only 76% for metronidazole, making metronidazole use strongly discouraged in this setting. 1, 2 Consider escalating to vancomycin 500 mg four times daily for 10 days in particularly severe cases. 3, 2

Fulminant Disease

High-dose oral vancomycin 500 mg four times daily PLUS intravenous metronidazole 500 mg every 8 hours 2

If oral administration is not possible due to ileus, add vancomycin retention enemas (500 mg in 100 mL normal saline four times daily) or administer vancomycin via nasogastric tube. 3

Intravenous tigecycline 50 mg twice daily for 14 days may be considered as salvage therapy, though this carries only marginal strength of recommendation. 3

Recurrent C. difficile Infection

First Recurrence

Treat as initial episode unless disease has progressed from non-severe to severe. 2 Fidaxomicin 200 mg twice daily for 10 days is preferred due to significantly lower rates of second recurrence. 3, 2

Second and Subsequent Recurrences

Use either:

  • Vancomycin tapered and pulsed regimen: Start with vancomycin 125 mg four times daily for 10 days, then gradually taper (e.g., 125 mg twice daily for a week, then once daily for a week, then every 2-3 days for 2-3 weeks) 3
  • Fidaxomicin 200 mg twice daily for 10 days 3, 2

Critical Management Principles

Immediately discontinue the inciting antibiotic if clinically feasible—this is the most important initial step. 1, 2 However, when patients require concomitant antibiotics for other infections, be aware that this compromises both initial response and durability of cure. 5 In such cases, fidaxomicin demonstrates superior efficacy over vancomycin (90.0% vs 79.4% cure rate with concomitant antibiotics). 5

Avoid antiperistaltic agents and opiates—these worsen outcomes and increase complications including toxic megacolon. 1, 2

Assess clinical response by 72 hours; if no improvement, escalate therapy immediately rather than waiting to complete the initial 10-day course. 1, 2 Treatment response typically requires 3-5 days. 1

Do not perform "test of cure" after treatment completion—only test symptomatic patients. 1, 2

Common Pitfalls to Avoid

Never use repeated or prolonged courses of metronidazole due to risk of cumulative and potentially irreversible neurotoxicity, particularly concerning in elderly patients. 1

Do not use higher doses of vancomycin (500 mg four times daily) for non-severe disease—the 125 mg dose is equally effective and less expensive. 3, 6

Do not continue ineffective therapy—if the patient shows no improvement by day 3-5 on metronidazole, escalate to vancomycin rather than completing the full 10-day course. 1

Surgical Intervention

Total abdominal colectomy with ileostomy is indicated for:

  • Perforation of the colon 3, 2
  • Systemic inflammation with deteriorating clinical condition despite maximal antibiotic therapy 3, 2
  • Toxic megacolon, acute abdomen, or severe ileus 3, 2

Operate before disease becomes very severe—serum lactate >5.0 mmol/L is a marker suggesting surgery should be performed urgently. 3, 2 A future alternative may be diverting loop ileostomy with colonic lavage combined with intracolonic antegrade vancomycin and intravenous metronidazole, though this requires further validation. 3

References

Guideline

Treatment Approaches for C. difficile Infection by Severity

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Treatment of Clostridium difficile Colitis

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Efficacy of fidaxomicin versus vancomycin as therapy for Clostridium difficile infection in individuals taking concomitant antibiotics for other concurrent infections.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.